Aminothiol reduction of ischemia-reperfusion-induced cell death
AssigneeObvia Pharmaceuticals Ltd
InventorsWilliam E. Fahl, Ningfeng Li
Life of this patent
Estimating the term…
Abstract
Members of the PrC-210 family of aminothiols, including PrC-211 and PrC-252, are shown to be highly effective in reducing ischemia-reperfusion injury in two preclinical models, including kidney transplant and myocardial infarct. Compositions and methods employing members of the PrC-210 family of aminothiols are disclosed for suppressing ischemia-reperfusion-induced cell and organ toxicities in a number of settings, significantly including organ transplant and myocardial infarct.
Claims16
A method of reducing an ischemia-reperfusion injury (IRI) in a subject, comprising administering to said subject an effective amount of a compound PrC-210, having the following structure
- or a pharmaceutically acid addition salt thereof.
A method for reducing cell death in a tissue of a subject having suffered from an ischemia-reperfusion injury (IRI), wherein a compound PrC-210 of the formula
- or a pharmaceutically acid addition salt thereof, is administered to the subject.
A method for reducing apoptosis in a tissue of a subject having suffered from an ischemia-reperfusion injury (IRI), wherein a compound PrC-210 of the formula
- or a pharmaceutically acid addition salt thereof, is administered to the subject.
A method for reducing caspase activity in a tissue of a subject having suffered from an ischemia-reperfusion injury (IRI), wherein a compound PrC-210 of the formula
- or a pharmaceutically acid addition salt thereof, is administered to the subject.
A method for reducing an ischemia-reperfusion injury (IRI) in a transplant organ, wherein a compound PrC-210 of the formula
- or pharmaceutically acceptable acid addition salt thereof, is administered to a transplant organ.
A method for reducing an ischemia-reperfusion injury (IRI) in a transplant organ, wherein a compound PrC-210 of the formula
- or pharmaceutically acceptable acid addition salt thereof, is administered to a donor of the transplant organ before organ removal from said donor.
A method for reducing an ischemia-reperfusion injury (IRI) in a transplant organ, wherein a compound PrC-210 of the formula
- or pharmaceutically acceptable acid addition salt thereof, is administered to a donor of the transplant organ during organ removal from the donor.
A method for reducing an ischemia-reperfusion injury (IRI) in a transplant organ, wherein a compound PrC-210 of the formula
- or pharmaceutically acceptable acid addition salt thereof is administered to a recipient of the transplant organ before or after organ transplantation.
Dependencies are inferred from the claim text.